LF15 + LP01™ (ACTIVAG)
Gynecology
Bacterial vaginosis
Supports vaginal health
Mitigates bacterial vaginosis (BV) symptoms
Inhibits Gardnerella vaginalis, causative agent of BV
1) LF15 400 million CFU + LP01v400 million CFU + Tara gum + FOS + Arabinogalactan
Blend
Finished dosage form
1) Vicariotto F. et al. Effectiveness of the two microorganisms L. fermentum LF15 and L. plantarum LP01, formulated in slow release vaginal tablets, in women affected by Bacterial Vaginosis: a pilot study. J Clin Gastroenterol. 2014; 48 Suppl:S106-112. DOI: 10.1097/MCG.0000000000000226
a) Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J. Clin. Gastroenterol. 2012;46 Suppl.S29-32. Doi: 10.1097/MCG.0b013e31826852b7
b) Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216. DOI: 10.35248/2329-8901.20.8.216
c) Amoruso A. et al. A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 2019; 7:214. Doi: 10.35248/2329-8901.19.7.214
